The company has developed a Positive Airway Pressure System that delivers therapeutic breathing pressure to patients, providing positive airway pressure during expiration and incipient apnea. The system includes a flow generator and patient interface for home use by adult patients weighing over 66 lbs. Somnera's technology is cloud-connected, enabling cloud-based data analytics, patient engagement, and automated reorder/subscription models. The company holds six US patents, has completed two clinical studies demonstrating equivalent effectiveness to CPAP, and will launch in the US in October 2020. The Somnera System is easy to use and complemented by new features designed to engage and delight customers. Sleep apnea affects 1 billion adults globally and is associated with a three-fold increase in all-cause mortality. The Somnera System has been strategically developed to fit within existing diagnosis, treatment, and reimbursement pathways, and the US FDA cleared it in June 2020.